Invokana and Invokamet (canagliflozin): Drug Safety Communication – New Information on Bone Fracture Risk and Decreased Bone Mineral Density

Audience: Endocrinology, Nursing, Family Practice ISSUE: FDA has strengthened the warning for the type 2 diabetes medicine canagliflozin (Invokana, Invokamet) related to the increased risk of bone fractures, and added new information about decreased…